 | • レポートコード：C-GIR20G2539 • 出版社/出版日：GlobalInfoResearch / 2019年12月30日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「良性前立腺過形成薬の世界市場2019年」は、グローバルにおける良性前立腺過形成薬市場を展望するレポートです。良性前立腺過形成薬のグローバル市場概観、企業動向、企業別シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどを掲載しています。 ・良性前立腺過形成薬の市場概観 ・良性前立腺過形成薬の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・良性前立腺過形成薬の企業別販売動向、市場シェア、市場集中度、競争動向 ・良性前立腺過形成薬の世界市場規模 ・良性前立腺過形成薬の北米市場分析（アメリカ、カナダ、メキシコ等） ・良性前立腺過形成薬のアメリカ市場規模推移 ・良性前立腺過形成薬のカナダ市場規模推移 ・良性前立腺過形成薬のメキシコ市場規模推移 ・良性前立腺過形成薬のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・良性前立腺過形成薬のドイツ市場規模推移 ・良性前立腺過形成薬のイギリス市場規模推移 ・良性前立腺過形成薬のロシア市場規模推移 ・良性前立腺過形成薬のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・良性前立腺過形成薬の日本市場規模推移 ・良性前立腺過形成薬の中国市場規模推移 ・良性前立腺過形成薬の韓国市場規模推移 ・良性前立腺過形成薬のインド市場規模推移 ・良性前立腺過形成薬の東南アジア市場規模推移 ・良性前立腺過形成薬の南米市場分析（ブラジル、アルゼンチン等） ・良性前立腺過形成薬の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・良性前立腺過形成薬の種類別分析/販売量、売上、市場シェア（アルファブロッカー、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他） ・良性前立腺過形成薬の用途別分析/市場規模（病院、クリニック、その他） ・良性前立腺過形成薬の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・良性前立腺過形成薬の販売チャネル・代理店・貿易業者・ディーラー分析 |
Description
Scope of the Report:
The global Benign Prostate Hyperplasia Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostate Hyperplasia Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Benign Prostate Hyperplasia Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostate Hyperplasia Drugs market by product type and applications/end industries.
Market Segment by Companies, this report covers
Sanofi
Teva Pharmaceuticals
Merck
Coloplast
Abbott Laboratories
Pfizer
Boehringer Ingelheim
Eli Lilly and Company
GlaxoSmithKline
Allergan
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Market Segment by Applications, can be divided into
Hospital
Clinic
Other
Table of Contents
1 Benign Prostate Hyperplasia Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostate Hyperplasia Drugs
1.2 Classification of Benign Prostate Hyperplasia Drugs by Types
1.2.1 Global Benign Prostate Hyperplasia Drugs Revenue Comparison by Types (2019-2024)
1.2.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Types in 2018
1.2.3 Alpha Blocker
1.2.4 5-Alpha Reductase Inhibitor
1.2.5 Phosphodiesterase-5 Inhibitor
1.2.6 Others
1.3 Global Benign Prostate Hyperplasia Drugs Market by Application
1.3.1 Global Benign Prostate Hyperplasia Drugs Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Benign Prostate Hyperplasia Drugs Market by Regions
1.4.1 Global Benign Prostate Hyperplasia Drugs Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Benign Prostate Hyperplasia Drugs Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostate Hyperplasia Drugs Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostate Hyperplasia Drugs Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostate Hyperplasia Drugs Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostate Hyperplasia Drugs Status and Prospect (2014-2024)
1.5 Global Market Size of Benign Prostate Hyperplasia Drugs (2014-2024)
2 Company Profiles
2.1 Sanofi
2.1.1 Business Overview
2.1.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Sanofi Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.2 Teva Pharmaceuticals
2.2.1 Business Overview
2.2.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.3 Merck
2.3.1 Business Overview
2.3.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.4 Coloplast
2.4.1 Business Overview
2.4.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Coloplast Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.5 Abbott Laboratories
2.5.1 Business Overview
2.5.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.7 Boehringer Ingelheim
2.7.1 Business Overview
2.7.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.8 Eli Lilly and Company
2.8.1 Business Overview
2.8.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.9 GlaxoSmithKline
2.9.1 Business Overview
2.9.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.10 Allergan
2.10.1 Business Overview
2.10.2 Benign Prostate Hyperplasia Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Allergan Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
3 Global Benign Prostate Hyperplasia Drugs Market Competition, by Players
3.1 Global Benign Prostate Hyperplasia Drugs Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostate Hyperplasia Drugs Players Market Share
3.2.2 Top 10 Benign Prostate Hyperplasia Drugs Players Market Share
3.3 Market Competition Trend
4 Global Benign Prostate Hyperplasia Drugs Market Size by Regions
4.1 Global Benign Prostate Hyperplasia Drugs Revenue and Market Share by Regions
4.2 North America Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
4.3 Europe Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
4.5 South America Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
5 North America Benign Prostate Hyperplasia Drugs Revenue by Countries
5.1 North America Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
5.2 USA Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
5.3 Canada Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
5.4 Mexico Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
6 Europe Benign Prostate Hyperplasia Drugs Revenue by Countries
6.1 Europe Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
6.2 Germany Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
6.3 UK Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
6.4 France Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
6.5 Russia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
6.6 Italy Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Countries
7.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
7.2 China Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
7.3 Japan Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
7.4 Korea Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
7.5 India Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
8 South America Benign Prostate Hyperplasia Drugs Revenue by Countries
8.1 South America Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
8.2 Brazil Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
8.3 Argentina Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
8.4 Colombia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Benign Prostate Hyperplasia Drugs by Countries
9.1 Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
9.2 Saudi Arabia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
9.3 UAE Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
9.4 Egypt Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
9.5 Nigeria Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
9.6 South Africa Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
10 Global Benign Prostate Hyperplasia Drugs Market Segment by Type
10.1 Global Benign Prostate Hyperplasia Drugs Revenue and Market Share by Type (2014-2019)
10.2 Global Benign Prostate Hyperplasia Drugs Market Forecast by Type (2019-2024)
10.3 Alpha Blocker Revenue Growth Rate (2014-2024)
10.4 5-Alpha Reductase Inhibitor Revenue Growth Rate (2014-2024)
10.5 Phosphodiesterase-5 Inhibitor Revenue Growth Rate (2014-2024)
10.6 Others Revenue Growth Rate (2014-2024)
11 Global Benign Prostate Hyperplasia Drugs Market Segment by Application
11.1 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Application (2014-2019)
11.2 Benign Prostate Hyperplasia Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Other Revenue Growth (2014-2019)
12 Global Benign Prostate Hyperplasia Drugs Market Size Forecast (2019-2024)
12.1 Global Benign Prostate Hyperplasia Drugs Market Size Forecast (2019-2024)
12.2 Global Benign Prostate Hyperplasia Drugs Market Forecast by Regions (2019-2024)
12.3 North America Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
12.4 Europe Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
12.6 South America Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Figure Benign Prostate Hyperplasia Drugs Picture
Table Product Specifications of Benign Prostate Hyperplasia Drugs
Table Global Benign Prostate Hyperplasia Drugs and Revenue (Million USD) Market Split by Product Type
Figure Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Types in 2018
Figure Alpha Blocker Picture
Figure 5-Alpha Reductase Inhibitor Picture
Figure Phosphodiesterase-5 Inhibitor Picture
Figure Others Picture
Table Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Application (2014-2024)
Figure Benign Prostate Hyperplasia Drugs Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Clinic Picture
Figure Other Picture
Table Global Market Benign Prostate Hyperplasia Drugs Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Benign Prostate Hyperplasia Drugs Type and Applications
Table Sanofi Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Type and Applications
Table Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Benign Prostate Hyperplasia Drugs Type and Applications
Table Merck Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Coloplast Basic Information, Manufacturing Base and Competitors
Table Coloplast Benign Prostate Hyperplasia Drugs Type and Applications
Table Coloplast Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table Abbott Laboratories Benign Prostate Hyperplasia Drugs Type and Applications
Table Abbott Laboratories Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Benign Prostate Hyperplasia Drugs Type and Applications
Table Pfizer Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Type and Applications
Table Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table Eli Lilly and Company Benign Prostate Hyperplasia Drugs Type and Applications
Table Eli Lilly and Company Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table GlaxoSmithKline Benign Prostate Hyperplasia Drugs Type and Applications
Table GlaxoSmithKline Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Allergan Basic Information, Manufacturing Base and Competitors
Table Allergan Benign Prostate Hyperplasia Drugs Type and Applications
Table Allergan Benign Prostate Hyperplasia Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Players (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue Share by Players (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Players in 2017
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Players in 2018
Figure Global Top 5 Players Benign Prostate Hyperplasia Drugs Revenue Market Share in 2018
Figure Global Top 10 Players Benign Prostate Hyperplasia Drugs Revenue Market Share in 2018
Figure Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Regions (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Regions (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Regions (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Regions in 2018
Figure North America Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Europe Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure South America Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table North America Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
Table North America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure North America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure North America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries in 2018
Figure USA Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Canada Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Mexico Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table Europe Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Countries (2014-2019)
Figure Europe Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure Europe Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries in 2018
Figure Germany Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure UK Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure France Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Russia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Italy Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries in 2018
Figure China Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Japan Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Korea Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure India Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table South America Benign Prostate Hyperplasia Drugs Revenue by Countries (2014-2019)
Table South America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure South America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure South America Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries in 2018
Figure Brazil Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Argentina Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Colombia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Share by Countries in 2018
Figure Saudi Arabia Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure UAE Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Egypt Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure Nigeria Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Figure South Africa Benign Prostate Hyperplasia Drugs Revenue and Growth Rate (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) by Type (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue Share by Type (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Type (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Type in 2018
Table Global Benign Prostate Hyperplasia Drugs Revenue Forecast by Type (2019-2024)
Figure Global Benign Prostate Hyperplasia Drugs Market Share Forecast by Type (2019-2024)
Figure Global Alpha Blocker Revenue Growth Rate (2014-2019)
Figure Global 5-Alpha Reductase Inhibitor Revenue Growth Rate (2014-2019)
Figure Global Phosphodiesterase-5 Inhibitor Revenue Growth Rate (2014-2019)
Figure Global Others Revenue Growth Rate (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue by Application (2014-2019)
Table Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Share by Application in 2018
Table Global Benign Prostate Hyperplasia Drugs Revenue Forecast by Application (2019-2024)
Figure Global Benign Prostate Hyperplasia Drugs Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Benign Prostate Hyperplasia Drugs Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Benign Prostate Hyperplasia Drugs Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
Figure Europe Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
Figure South America Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Benign Prostate Hyperplasia Drugs Revenue Market Forecast (2019-2024)
世界の良性前立腺過形成（BPH）治療市場予測（～2024年） Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infec…- 良性再発性肝内胆汁うっ滞（BRIC）画像診断装置の世界市場 2019年版：種類別（X線、MRI、CT、核イメージング）、用途別（病院、イメージングセンター） Scope of the Report: The worldwide market for Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Resea…
- 世界のがんホルモン療法薬市場予測（～2024年） Hormone Therapy, (also called hormonal therapy, hormone treatment, or endocrine therapy) is a cancer treatment that blocks or lowers the growth of cancer that uses hormones to grow. Doctors use it to treat some cancers such as breast and prostate cancer. Scope of the Report: The global Cancer Hormon…
- 前立腺特異抗原（PSA）テストの世界市場 2019年版：種類別（CLIA法、ELISA法）、用途別（スクリーニング、治療後モニタリング、その他） Scope of the Report: The global Prostate-specific Antigen (PSA) Testing market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especi…
- 前立腺がん市場：世界及び中国市場分析・予測（～2024年） Prostate Cancer Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Prostate Cancer industry with a focus on the Chinese market. The report provides key statistics on the market status of the Prostate Cancer manufacturers and is a…